CN102198110B - Tenofovir disoproxil fumarate dispersible tablets and preparation method thereof - Google Patents
Tenofovir disoproxil fumarate dispersible tablets and preparation method thereof Download PDFInfo
- Publication number
- CN102198110B CN102198110B CN2011101411248A CN201110141124A CN102198110B CN 102198110 B CN102198110 B CN 102198110B CN 2011101411248 A CN2011101411248 A CN 2011101411248A CN 201110141124 A CN201110141124 A CN 201110141124A CN 102198110 B CN102198110 B CN 102198110B
- Authority
- CN
- China
- Prior art keywords
- fumaric acid
- pyrrole furan
- acid tenofovir
- filler
- surfactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses tenofovir disoproxil fumarate dispersible tablets and a preparation method thereof. The tenofovir disoproxil fumarate dispersible tablets are prepared from tenofovir disoproxil fumarate as an effective pharmaceutical ingredient and pharmaceutically acceptable auxiliary ingredients, wherein the pharmaceutically acceptable auxiliary ingredients comprise a filler, a disintegrant, a lubricant, a surfactant and a flavoring agent. The tenofovir disoproxil fumarate dispersible tablets prepared by the invention have appropriate hardness, small weight difference, bright and clean tablet surfaces and good taste, fully meet the requirements on the disintegration time and dispersion uniformity of dispersible tablets, and notably improve the pharmaceutical bioavailability, and in addition, the tenofovir disoproxil fumarate dispersible tablets have quick dissolution rate, the dissolution percentage of the product is about 80-90% in 2 minutes, and the product is almost completely dissolved in 5 minutes.
Description
(1) technical field
The present invention relates to the dispersible tablet formulation and preparation method thereof of the medicine fumaric acid tenofovir two pyrrole furan esters of a kind of anti AIDS virus (HIV), hepatitis B virus (HBV).
(2) background technology
Fumaric acid tenofovir two pyrrole furan esters (English name: be the esters prodrug of tenofovir Tenofovir disoproxil fumarate), belong to novel nucleoside acids RTI, can suppress duplicating of HIV, HBV virus.Its main mechanism is that oral posthydrolysis is a tenofovir, and tenofovir is generated the metabolite tenofovir diphosphonic acid with pharmacologically active by the cell kinase phosphorylation; The latter and 5 '-deoxyadenosine triphosphate acid competition; Participate in the synthetic of viral DNA, behind the entering viral DNA, because shortage 3 '-the 0H group; Thereby cause DNA to prolong being obstructed, and then the duplicating of blocking virus.Show that from present clinical practice it has significant anti-HIV, HBV virus curative effect, and its toxicity to human body is very little, is expected to become a line medication.
Fumaric acid tenofovir two pyrrole furan ester conventional tablets in the U.S., European Union, Turkey, Australia, New Zealand, add take, listing such as China, be used to treat HIV or HBV.This medicine is at existing report with in using; What really only relate to is the medicine of its conventional tablet dosage form; One all need help swallow or directly swallow the conventional tablet medicine by drinking-water when taking; This just to some like old people, child with there is patient's compliance of dysphagia poor, also have in the use of going out or lack under the specific condition such as drinking water also can receive very big restriction.In addition, conventional tablet one onset is slow comparatively speaking, to reach the peak slow, and dispersible tablet disintegrate result of extraction is good, can significantly improve bioavailability.
(3) summary of the invention
The technical problem that the present invention will solve provides a kind of fumaric acid tenofovir two pyrrole furan ester dispersible tablet drug preparations, and this dispersible tablet is than existing conventional tablet, and disintegration time is short, the medicine stripping is rapid, rapid-action, bioavailability is high, and taking convenience.
For solving the problems of the technologies described above, the present invention adopts following technical scheme:
A kind of fumaric acid tenofovir two pyrrole furan ester dispersible tablets; Be to be the active drug composition with fumaric acid tenofovir two pyrrole furan esters; Process jointly with the acceptable auxiliary element of pharmacy, the acceptable auxiliary element of described pharmacy comprises filler, disintegrating agent, lubricant, surfactant and correctives; With 100%, the percentage by weight of each raw material components is represented as follows in the gross weight of fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, lubricant, surfactant and correctives:
Described filler is selected from following a kind of or any several kinds combination: microcrystalline Cellulose, lactose, sucrose, pregelatinized Starch, starch, sorbitol, mannitol, xylitol;
Described disintegrating agent is selected from following a kind of or any several kinds combination: low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone, cross-linking sodium carboxymethyl cellulose, carboxymethyl starch sodium, sodium carboxymethyl cellulose, carboxymethylcellulose calcium;
Described lubricant is selected from following a kind of or any several kinds combination: magnesium stearate, calcium stearate, stearic acid, Pulvis Talci, micropowder silica gel, Polyethylene Glycol;
Surfactant is selected from following a kind of or any several kinds combination: sodium lauryl sulphate, Stepanol MG, dodecyl sulfo-sodium succinate, Tween 80;
Described correctives is selected from following a kind of or any several kinds combination: aspartame, cyclamate, glycyrrhizin, stevioside, saccharin sodium.
Further, the percentage by weight of the preferred described fumaric acid tenofovir two pyrrole furan esters of the present invention, filler, disintegrating agent, lubricant, surfactant and correctives is represented as follows:
Further, the percentage by weight of the preferred described fumaric acid tenofovir two pyrrole furan esters of the present invention, filler, disintegrating agent, lubricant, surfactant and correctives is represented as follows:
Further, described filler is preferred one of following: the combination of microcrystalline Cellulose 10～35%, lactose 10～40% and mannitol 0～30%, the combination of microcrystalline Cellulose 10～35%, pregelatinized Starch 10～40% and mannitol 0～30%.Above-mentioned percentage ratio also is that gross weight in fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, lubricant, surfactant and correctives is with 100%.
Further, described filler is preferred one of following: the combination of microcrystalline Cellulose 10～25%, lactose 10～25% and mannitol 0～20%, the combination of microcrystalline Cellulose 10～25%, pregelatinized Starch 15～25% and mannitol 0～20%.
Further, preferred following one or both the combination of described disintegrating agent: low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone.
Further, preferred following one or both the combination of described lubricant: magnesium stearate, micropowder silica gel.
Further, described surfactant preferably sodium dodecyl sulfate.
Further, the preferred aspartame of described correctives.
Fumaric acid tenofovir two pyrrole furan ester dispersible tablets of the present invention are the active drug composition with fumaric acid tenofovir two pyrrole furan esters, process jointly with the acceptable auxiliary element of pharmacy, and the acceptable auxiliary element of described pharmacy can also comprise binding agent; Said binding agent can be selected from following a kind of: water, ethanol, ethanol water, amidin; The polyvidone aqueous solution, polyvidone alcoholic solution, polyvidone ethanol water; The hydroxypropyl emthylcellulose aqueous solution, hydroxypropyl emthylcellulose alcoholic solution, hydroxypropyl emthylcellulose ethanol water; Sodium carboxymethyl cellulose solution, sodium carboxymethyl cellulose alcoholic solution, sodium carboxymethyl cellulose ethanol water; Hydroxypropyl cellulose aqueous solution, hydroxypropyl cellulose alcoholic solution, hydroxypropyl cellulose ethanol water.
Further, described binding agent is preferred one of following: mass fraction is that 2～10% amidin, mass fraction are that 2～10% polyvidone aqueous solution, mass fraction are 2～10% hydroxypropyl emthylcellulose aqueous solution.
Among the present invention, the addition of said binding agent is recommended as 0.1～0.9ml/g in the gross weight of fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, lubricant, surfactant and correctives, is preferably 0.25～0.8ml/g.
Preferred version of the present invention is:
A kind of fumaric acid tenofovir two pyrrole furan ester dispersible tablets; Be to be the active drug composition with fumaric acid tenofovir two pyrrole furan esters; Process jointly with the acceptable auxiliary element of pharmacy, the acceptable auxiliary element of described pharmacy is made up of filler, disintegrating agent, lubricant, surfactant and correctives; With 100%, the percentage by weight of each raw material components is represented as follows in the gross weight of fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, lubricant, surfactant and correctives:
It is one of following that described filler is selected from: the combination of microcrystalline Cellulose 10～25%, lactose 10～25% and mannitol 0～20%, the combination of microcrystalline Cellulose 10～25%, pregelatinized Starch 15～25% and mannitol 0～20%;
Described disintegrating agent is selected from following one or both combination: low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone;
Described lubricant is selected from following one or both combination: magnesium stearate, micropowder silica gel;
Described surfactant is selected from sodium lauryl sulphate;
Described correctives is selected from aspartame.
Another preferred version of the present invention is:
A kind of fumaric acid tenofovir two pyrrole furan ester dispersible tablets; Be to be the active drug composition with fumaric acid tenofovir two pyrrole furan esters; Process jointly with the acceptable auxiliary element of pharmacy, the acceptable auxiliary element of described pharmacy is made up of filler, disintegrating agent, lubricant, surfactant, correctives and binding agent; The addition of said binding agent is counted 0.25～0.8ml/g with the gross weight of fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, lubricant, surfactant and correctives; With 100%, represent as follows by shared separately percentage by weight in the gross weight of fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, lubricant, surfactant and correctives for the addition of said filler, disintegrating agent, lubricant, surfactant, correctives:
It is one of following that described filler is selected from: the combination of microcrystalline Cellulose 10～25%, lactose 10～25% and mannitol 0～20%, the combination of microcrystalline Cellulose 10～25%, pregelatinized Starch 15～25% and mannitol 0～20%;
Described disintegrating agent is selected from following one or both combination: low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone;
Described lubricant is selected from following one or both combination: magnesium stearate, micropowder silica gel;
Described surfactant is selected from sodium lauryl sulphate;
Described correctives is selected from aspartame;
It is one of following that described binding agent is selected from: mass fraction is that 2～10% amidin, mass fraction are that 2～10% polyvidone aqueous solution, mass fraction are 2～10% hydroxypropyl emthylcellulose aqueous solution.
The above-mentioned fumaric acid tenofovir two pyrrole furan ester dispersible tablet drug preparations of the present invention can obtain through wet granulation or dry granulation or fluidized bed granulation or spray granulation or direct powder compression preparation.
Wherein the process of direct powder compression is:
A kind of method for preparing of fumaric acid tenofovir two pyrrole furan ester dispersible tablets comprises the following steps:
1) with fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, correctives, lubricant, surfactant abundant mix homogeneously and pulverized 100 mesh sieves in proportion;
2) behind the mixing, measure content, tab weight is processed sheet.
Wherein, the process of wet granule compression tablet method is:
A kind of method for preparing of fumaric acid tenofovir two pyrrole furan ester dispersible tablets, the acceptable auxiliary element of described pharmacy also comprises binding agent, said method for preparing comprises the following steps:
A) with fumaric acid tenofovir two pyrrole furan esters, filler and correctives or fumaric acid tenofovir two pyrrole furan esters, filler, correctives and the abundant mix homogeneously of disintegrating agent and pulverized 100 mesh sieves;
B) add binding agent, 20 mesh sieve wet granulations;
C) 50～60 ℃ of dryings are after 2～4 hours, 18 mesh sieve granulate;
D) add lubricant and surfactant or lubricant, surfactant and disintegrating agent again, behind the mixing, measure content, tab weight is processed sheet;
In above-mentioned steps (a) and the step (d), one of them step need add disintegrating agent.
In the above-mentioned wet granule compression tablet procedure, disintegrating agent is processed granule with the prescription powder, is referred to as addition in the disintegrating agent; Disintegrating agent mixes the back tabletting and is referred to as the outer addition of disintegrating agent with dried granules; Add in the disintegrating agent and add the disintegration rate that all can influence dispersible tablet, can adopt interior addition, also can adopt outer addition, can also in add, add common use; Interiorly add, when adding common use, disintegrating agent can be identical, also can be different; These preparations and processing method all are as well known to those skilled in the art and familiar.
Compared with prior art, beneficial effect of the present invention is:
1, the fumaric acid tenofovir two pyrrole furan ester dispersible tablets that make of the present invention have suitable hardness, weight differential little, unilateral bright and clean, mouthfeel good; Meet the requirement of dispersible tablet disintegration and dispersing uniformity fully; Dissolution rate is fast, in 2min the stripping percentage rate of these article about 80-90%, basically all strippings of these article in 5min.
Therefore as the said medicine of the present invention of intestines and stomach route of administration; Its dispersing uniformity and dissolution and all very desirable to sheltering of adverse drug taste; Can solve some old peoples, child satisfactorily and the patient of dysphagia is arranged and go out or lack the problem of taking under the specific condition such as drinking water, when taking medicine is contained in and suck clothes in the mouth or medicine is put into warm water disperse to swallow; Suck clothes, be dispersed in and swallow in the water or directly swallow for optional the selecting of usual crowd; Foregoing invention solved well usual crowd and very the crowd can satisfy different patients' medication demand to the compliance of this medicine; Above-mentioned in vitro tests shows that this pharmaceutical preparation can significantly improve bioavailability.
2, said medicine preparation of the present invention can directly use conventional tablet pharmaceutical equipment to produce and use the pressing process preparation, need not overlapping investment, and preparation technology is simple and convenient, has good market prospect.
(4) specific embodiment
Below again foregoing of the present invention is done further to specify through specific embodiment.But should this scope that is interpreted as the above-mentioned theme of the present invention only be confined to following instance.Under the situation that does not break away from the above-mentioned technological thought of the present invention, various replacements or change according to ordinary skill knowledge and customary means are made all should comprise within the scope of the invention.
Embodiment 1:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, mannitol, microcrystalline Cellulose, lactose, low-substituted hydroxypropyl cellulose, the abundant mix homogeneously of aspartame and pulverized 100 mesh sieves; Process 20 order wet granulars with an amount of 5% amidin; After 3 hours, 18 mesh sieve granulate are behind adding polyvinylpolypyrrolidone, sodium lauryl sulphate, the abundant mixing of magnesium stearate in 55 ℃ of dryings; Measure content, tab weight is processed sheet.
Embodiment 2:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, mannitol, microcrystalline Cellulose, lactose, low-substituted hydroxypropyl cellulose, the abundant mix homogeneously of aspartame and pulverized 100 mesh sieves; Process 20 order wet granulars with an amount of 3% polyvidone aqueous solution; After 3.5 hours, 18 mesh sieve granulate are behind adding polyvinylpolypyrrolidone, sodium lauryl sulphate, micropowder silica gel, the abundant mixing of magnesium stearate in 55 ℃ of dryings; Measure content, tab weight is processed sheet.
Embodiment 3:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, microcrystalline Cellulose, lactose, low-substituted hydroxypropyl cellulose, the abundant mix homogeneously of aspartame and pulverized 100 mesh sieves; Process 20 order wet granulars with an amount of 5% amidin; After 3 hours, 18 mesh sieve granulate are behind adding polyvinylpolypyrrolidone, sodium lauryl sulphate, the abundant mixing of magnesium stearate in 50 ℃ of dryings; Measure content, tab weight is processed sheet.
Embodiment 4:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, mannitol, microcrystalline Cellulose, pregelatinized Starch, low-substituted hydroxypropyl cellulose, the abundant mix homogeneously of aspartame and pulverized 100 mesh sieves; Process 20 order wet granulars with an amount of 5% polyvidone aqueous solution; After 3 hours, 18 mesh sieve granulate are behind adding polyvinylpolypyrrolidone, sodium lauryl sulphate, the abundant mixing of magnesium stearate in 55 ℃ of dryings; Measure content, tab weight is processed sheet.
Embodiment 5:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, mannitol, microcrystalline Cellulose, pregelatinized Starch, low-substituted hydroxypropyl cellulose, the abundant mix homogeneously of aspartame and pulverized 100 mesh sieves; Process 20 order wet granulars with an amount of 4% hydroxypropyl emthylcellulose aqueous solution; After 3.5 hours, 18 mesh sieve granulate are behind adding polyvinylpolypyrrolidone, sodium lauryl sulphate, micropowder silica gel, the abundant mixing of magnesium stearate in 55 ℃ of dryings; Measure content, tab weight is processed sheet.
Embodiment 6:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, microcrystalline Cellulose, pregelatinized Starch, low-substituted hydroxypropyl cellulose, the abundant mix homogeneously of aspartame and pulverized 100 mesh sieves; Process 20 order wet granulars with an amount of 8% amidin; After 3 hours, 18 mesh sieve granulate are behind adding polyvinylpolypyrrolidone, sodium lauryl sulphate, the abundant mixing of magnesium stearate in 50 ℃ of dryings; Measure content, tab weight is processed sheet.
Embodiment 7:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, microcrystalline Cellulose, lactose, 51.2g polyvinylpolypyrrolidone, the abundant mix homogeneously of aspartame and pulverized 100 mesh sieves; Process 20 order wet granulars with an amount of 5% polyvidone aqueous solution; After 3 hours, 18 mesh sieve granulate are behind adding 44g polyvinylpolypyrrolidone, sodium lauryl sulphate, the abundant mixing of magnesium stearate in 55 ℃ of dryings; Measure content, tab weight is processed sheet.
Embodiment 8:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, microcrystalline Cellulose, lactose, 50g low-substituted hydroxypropyl cellulose, the abundant mix homogeneously of aspartame and pulverized 100 mesh sieves; Process 20 order wet granulars with an amount of 5% amidin; After 3 hours, 18 mesh sieve granulate are behind adding 52.5g low-substituted hydroxypropyl cellulose, sodium lauryl sulphate, the abundant mixing of magnesium stearate in 55 ℃ of dryings; Measure content, tab weight is processed sheet.
Embodiment 9:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, mannitol, microcrystalline Cellulose, lactose, low-substituted hydroxypropyl cellulose, the abundant mix homogeneously of aspartame and pulverized 100 mesh sieves; Process 20 order wet granulars with an amount of 5% polyvidone aqueous solution; After 2.5 hours, 18 mesh sieve granulate are behind adding polyvinylpolypyrrolidone, sodium lauryl sulphate, the abundant mixing of magnesium stearate in 55 ℃ of dryings; Measure content, tab weight is processed sheet.
Embodiment 10:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, mannitol, microcrystalline Cellulose, lactose, low-substituted hydroxypropyl cellulose, the abundant mix homogeneously of aspartame and pulverized 100 mesh sieves; Process 20 order wet granulars with an amount of 5% amidin; After 3 hours, 18 mesh sieve granulate are behind adding polyvinylpolypyrrolidone, sodium lauryl sulphate, the abundant mixing of magnesium stearate in 55 ℃ of dryings; Measure content, tab weight is processed sheet.
Embodiment 11:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, microcrystalline Cellulose, lactose, polyvinylpolypyrrolidone, aspartame, sodium lauryl sulphate, the abundant mix homogeneously of magnesium stearate and pulverized 100 mesh sieves, measure content, the heavy directly compacting of tab is in blocks.
Embodiment 12:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, microcrystalline Cellulose, pregelatinized Starch, low-substituted hydroxypropyl cellulose, aspartame, sodium lauryl sulphate, the abundant mix homogeneously of magnesium stearate and pulverized 100 mesh sieves; Measure content, the heavy directly compacting of tab in flakes.
Embodiment 13:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, microcrystalline Cellulose, lactose, polyvinylpolypyrrolidone, aspartame, sodium lauryl sulphate, the abundant mix homogeneously of magnesium stearate and pulverized 100 mesh sieves, measure content, the heavy directly compacting of tab is in blocks.
Embodiment 14:
Prescription:
Method for preparing: with fumaric acid tenofovir two pyrrole furan esters, microcrystalline Cellulose, pregelatinized Starch, low-substituted hydroxypropyl cellulose, aspartame, sodium lauryl sulphate, the abundant mix homogeneously of magnesium stearate and pulverized 100 mesh sieves; Measure content, the heavy directly compacting of tab in flakes.
The analytical test result of the fumaric acid tenofovir two pyrrole furan ester dispersible tablets that the above embodiment of the present invention is prepared:
(1) weight differential of the prepared fumaric acid tenofovir two pyrrole furan ester dispersible tablets of above embodiment little, unilateral bright and clean, hardness is moderate, mouthfeel good.
(2) the dispersing uniformity result of the test shows: according to the method for two regulations of 2010 editions Chinese Pharmacopoeias, get 6 of these article, put in the 250ml beaker, add about 20 ℃ water 100ml, and jolting 3 minutes, the whole disintegrates of above embodiment dispersible tablet are also passed through sieve No. two.
(3) the dissolution result of the test shows: according to dissolution method (2010 editions two appendix XC second methods of Chinese Pharmacopoeia); With 0.01mol/L hydrochloric acid solution 900ml is dissolution medium; Rotating speed is that per minute 50 changes, and operation is in accordance with the law measured every stripping quantity according to ultraviolet visible spectrophotometry; The result be the stripping percentage rate of these article in 2min about 80-90%, basically all strippings of these article in 5min.The result sees the following form 1.
The accumulation stripping percentage rate of each each time point of embodiment of table 1.
Claims (8)
1. fumaric acid tenofovir two pyrrole furan ester dispersible tablets; Be to be the active drug composition with fumaric acid tenofovir two pyrrole furan esters; Process jointly with the acceptable auxiliary element of pharmacy, the acceptable auxiliary element of described pharmacy comprises filler, disintegrating agent, lubricant, surfactant and correctives; With 100%, the percentage by weight of each raw material components is represented as follows in the gross weight of fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, lubricant, surfactant and correctives:
It is one of following that described filler is selected from: the combination of microcrystalline Cellulose 10～35%, lactose 10～40% and mannitol 0～30%, the combination of microcrystalline Cellulose 10～35%, pregelatinized Starch 10～40% and mannitol 0～30%;
Described disintegrating agent is selected from following one or both combination: low-substituted hydroxypropyl cellulose, polyvinylpolypyrrolidone;
Described lubricant is selected following one or both combination: magnesium stearate, micropowder silica gel;
Described surfactant is a sodium lauryl sulphate;
Described correctives is an aspartame.
2. fumaric acid tenofovir two pyrrole furan ester dispersible tablets as claimed in claim 1; It is one of following to it is characterized in that described filler is selected from: the combination of microcrystalline Cellulose 10～25%, lactose 10～25% and mannitol 0～20%, the combination of microcrystalline Cellulose 10～25%, pregelatinized Starch 15～25% and mannitol 0～20%.
3. according to claim 1 or claim 2 fumaric acid tenofovir two pyrrole furan ester dispersible tablets is characterized in that the acceptable auxiliary element of described pharmacy also comprises binding agent, and said binding agent is selected from following a kind of: water; Ethanol, ethanol water, amidin; The polyvidone aqueous solution, polyvidone alcoholic solution, polyvidone ethanol water; The hydroxypropyl emthylcellulose aqueous solution, hydroxypropyl emthylcellulose alcoholic solution, hydroxypropyl emthylcellulose ethanol water; Sodium carboxymethyl cellulose solution, sodium carboxymethyl cellulose alcoholic solution, sodium carboxymethyl cellulose ethanol water; Hydroxypropyl cellulose aqueous solution, hydroxypropyl cellulose alcoholic solution, hydroxypropyl cellulose ethanol water.
4. fumaric acid tenofovir two pyrrole furan ester dispersible tablets as claimed in claim 3 is characterized in that the addition of said binding agent is counted 0.1 ~ 0.9 ml/g with the gross weight of fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, lubricant, surfactant and correctives.
5. fumaric acid tenofovir two pyrrole furan ester dispersible tablets as claimed in claim 2 is characterized in that the acceptable auxiliary element of described pharmacy is made up of filler, disintegrating agent, lubricant, surfactant and correctives.
6. fumaric acid tenofovir two pyrrole furan ester dispersible tablets as claimed in claim 2; It is characterized in that the acceptable auxiliary element of described pharmacy is made up of filler, disintegrating agent, lubricant, surfactant, correctives and binding agent, said binding agent is selected from following a kind of: mass fraction is that 2～10% amidin, mass fraction are that 2～10% polyvidone aqueous solution, mass fraction are 2～10% hydroxypropyl emthylcellulose aqueous solution; The addition of said binding agent is counted 0.25 ~ 0.8ml/g with the gross weight of fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, lubricant, surfactant and correctives.
7. the method for preparing of fumaric acid tenofovir two pyrrole furan ester dispersible tablets as claimed in claim 1 comprises the following steps:
1) with fumaric acid tenofovir two pyrrole furan esters, filler, disintegrating agent, correctives, lubricant, the abundant mix homogeneously of surfactant and pulverized 100 mesh sieves;
2) behind the mixing, measure content, tab weight is processed sheet.
8. the method for preparing of fumaric acid tenofovir two pyrrole furan ester dispersible tablets as claimed in claim 3 is characterized in that the acceptable auxiliary element of described pharmacy also comprises binding agent, and said method for preparing comprises the following steps:
A) with fumaric acid tenofovir two pyrrole furan esters, filler and correctives or fumaric acid tenofovir two pyrrole furan esters, filler, correctives and the abundant mix homogeneously of disintegrating agent and pulverized 100 mesh sieves;
B) add binding agent, 20 mesh sieve wet granulations;
C) 50～60 ℃ of dryings are after 2～4 hours, 18 mesh sieve granulate;
D) add lubricant and surfactant or lubricant, surfactant and disintegrating agent again, behind the mixing, measure content, tab weight is processed sheet;
In above-mentioned steps (a) and the step (d), one of them step need add disintegrating agent.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101411248A CN102198110B (en) | 2011-05-27 | 2011-05-27 | Tenofovir disoproxil fumarate dispersible tablets and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2011101411248A CN102198110B (en) | 2011-05-27 | 2011-05-27 | Tenofovir disoproxil fumarate dispersible tablets and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102198110A CN102198110A (en) | 2011-09-28 |
| CN102198110B true CN102198110B (en) | 2012-11-14 |
Family
ID=44659269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2011101411248A Active CN102198110B (en) | 2011-05-27 | 2011-05-27 | Tenofovir disoproxil fumarate dispersible tablets and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102198110B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103830192A (en) * | 2012-11-27 | 2014-06-04 | 安徽贝克生物制药有限公司 | Tenofovir disoproxil fumarate tablets allowing direct powder compression and preparation method thereof |
| CN103230404A (en) * | 2013-05-14 | 2013-08-07 | 福建广生堂药业股份有限公司 | Novel use of adefovir dipivoxil or medicinal salt thereof |
| CN103336067B (en) * | 2013-05-29 | 2015-01-21 | 东北制药集团股份有限公司 | High-performance liquid detection method for detecting tenofovir diethyl ester content |
| CN103330683B (en) * | 2013-06-26 | 2014-12-03 | 神威药业集团有限公司 | Tenofovir disoproxil fumarate fine granules |
| CN103705478B (en) * | 2013-12-23 | 2020-02-07 | 浙江华海药业股份有限公司 | Oral tablet containing tenofovir disoproxil fumarate |
| CN104739784A (en) * | 2013-12-25 | 2015-07-01 | 辰欣药业股份有限公司 | Method for preparing tenofovir disoproxil fumarate tablet |
| CN105125511A (en) * | 2014-05-30 | 2015-12-09 | 北京星昊医药股份有限公司 | Tenofovir disoproxil fumarate tablet and preparation method thereof |
| CN105213332A (en) * | 2014-06-17 | 2016-01-06 | 广州朗圣药业有限公司 | Oral tablet of a kind of tenofovir disoproxil fumarate and preparation method thereof |
| CN111407736A (en) * | 2020-03-30 | 2020-07-14 | 苏州弘森药业股份有限公司 | Preparation process of tenofovir disoproxil fumarate tablets |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1738628A (en) * | 2003-01-14 | 2006-02-22 | 吉里德科学公司 | Compositions and methods for combination antiviral therapy |
| CN101199849A (en) * | 2007-12-07 | 2008-06-18 | 北京润德康医药技术有限公司 | Compound for medicine containing nucleoside (acid) and plant extract, preparing method and function thereof |
| CN101229178A (en) * | 2007-11-27 | 2008-07-30 | 北京润德康医药技术有限公司 | Compound medicine compounds containing adefovir dipivoxil, preparing method and uses thereof |
| CN101278938A (en) * | 2008-03-20 | 2008-10-08 | 黑龙江加州国际投资咨询有限公司 | Compound preparation of tenofovir and entecavir and its application against hepatitis B virus |
| CN101781335A (en) * | 2010-03-04 | 2010-07-21 | 福建广生堂药业有限公司 | New tenofovir disoproxil fumarate crystal and preparation method thereof |
-
2011
- 2011-05-27 CN CN2011101411248A patent/CN102198110B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1738628A (en) * | 2003-01-14 | 2006-02-22 | 吉里德科学公司 | Compositions and methods for combination antiviral therapy |
| CN101229178A (en) * | 2007-11-27 | 2008-07-30 | 北京润德康医药技术有限公司 | Compound medicine compounds containing adefovir dipivoxil, preparing method and uses thereof |
| CN101199849A (en) * | 2007-12-07 | 2008-06-18 | 北京润德康医药技术有限公司 | Compound for medicine containing nucleoside (acid) and plant extract, preparing method and function thereof |
| CN101278938A (en) * | 2008-03-20 | 2008-10-08 | 黑龙江加州国际投资咨询有限公司 | Compound preparation of tenofovir and entecavir and its application against hepatitis B virus |
| CN101781335A (en) * | 2010-03-04 | 2010-07-21 | 福建广生堂药业有限公司 | New tenofovir disoproxil fumarate crystal and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102198110A (en) | 2011-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102198110B (en) | Tenofovir disoproxil fumarate dispersible tablets and preparation method thereof | |
| US20070059360A1 (en) | Water-dispersible anti-retroviral pharmaceutical compositions | |
| WO2000078292A1 (en) | Quickly disintegrating solid preparations | |
| CN102512393A (en) | Oral disintegrated tablet containing tolvaptan | |
| CN101103980A (en) | Fexofenadine medicinal composition | |
| KR101562608B1 (en) | Compound chemical medicine acting on respiratory disease, preparation process and use thereof | |
| CN107913256A (en) | A kind of macitentan oral disnitegration tablet for treating pulmonary hypertension and preparation method thereof | |
| CN101461788B (en) | Phloroglucine orally disintegrating tablet and preparation method thereof | |
| CN102631329A (en) | Oral paroxetine disintegrating tablet and preparation process thereof | |
| CN102451162A (en) | Olanzapine medicine absorbed through oral mucosa | |
| CN112426408B (en) | Melatonin composition and preparation process thereof | |
| CN104644574A (en) | A sildenafil citrate taste-masking preparation | |
| CN101401795A (en) | Imatinib mesylate orally disintegrating tablets and preparation method thereof | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN101011362A (en) | Dispersible tablet of pidotimod and its preparing process and use | |
| CN103040780A (en) | Rapidly disintegrating pramipexole tablet drug composition and preparation method thereof | |
| CN114129528B (en) | Novel sildenafil citrate preparation with clinical advantages and preparation process and application thereof | |
| CN102860986A (en) | Stable taste-masking levocetirizine medicine composition and preparation method thereof | |
| CN102626410A (en) | Pharmaceutical composition containing roflumilast | |
| CN115177595A (en) | Oxagolide sodium tablet and preparation method thereof | |
| CN105213332A (en) | Oral tablet of a kind of tenofovir disoproxil fumarate and preparation method thereof | |
| CN100506237C (en) | Seabuckthorn preparation and its preparing process | |
| CN101292977B (en) | Pharmaceutical combination with stable strontium ranelate and its preparations | |
| AU2013347264B2 (en) | Dispersible tablet | |
| CN100348180C (en) | Oral disintegration tablet of tramadol hydrochloride and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent for invention or patent application | ||
| CB02 | Change of applicant information |
Address after: 311227 Nanyang Economic Development Zone, Hangzhou, Zhejiang, China, Xiaoshan Applicant after: Hangzhou Coben Pharmaceutical Co., Ltd. Co-applicant after: Jiangsu Branch of the Pharmaceutical Chemical Co., Ltd. Co-applicant after: Hangzhou Coben Pharmaceutical Research Co., Ltd. Address before: 310004, Haihua Plaza, 658 Jianguo North Road, Zhejiang, Hangzhou 17B Applicant before: Hangzhou Coben Pharmaceutical Co., Ltd. Co-applicant before: Jiangsu Branch of the Pharmaceutical Chemical Co., Ltd. Co-applicant before: Hangzhou Coben Pharmaceutical Research Co., Ltd. |
|
| CB03 | Change of inventor or designer information |
Inventor after: Shi Lei Inventor after: You Jinzong Inventor after: Jiang Shanhui Inventor after: Ren Haihua Inventor before: Shi Lei Inventor before: Yu Xiaofen Inventor before: You Jinzong Inventor before: Jiang Shanhui |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: SHI LEI YU XIAOFEN YOU JINZONG JIANG SHANHUI TO: SHI LEI YOU JINZONG JIANG SHANHUI REN HAIHUA |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 311227 Nanyang Economic Development Zone, Hangzhou, Zhejiang, China, Xiaoshan Patentee after: Hangzhou Coben Pharmaceutical Co.,Ltd. Patentee after: Jiangsu Cobain Pharmaceutical Co., Ltd. Patentee after: Hangzhou Coben Pharmaceutical Research Co.,Ltd. Address before: 311227 Nanyang Economic Development Zone, Hangzhou, Zhejiang, China, Xiaoshan Patentee before: Hangzhou Coben Pharmaceutical Co.,Ltd. Patentee before: Jiangsu Coben Medical Chemical Co.,Ltd. Patentee before: Hangzhou Coben Pharmaceutical Research Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190116 Address after: Room 601, F Building, 1378 Wenyi West Road, Cangqian Street, Yuhang District, Hangzhou City, Zhejiang Province Co-patentee after: Jiangsu Cobain Pharmaceutical Co., Ltd. Patentee after: Hangzhou Kang Kang Pharmaceutical Technology Co., Ltd. Co-patentee after: Hangzhou Coben Pharmaceutical Research Co., Ltd. Address before: 311227 Nanyang Economic Development Zone, Xiaoshan, Hangzhou, Zhejiang Province Co-patentee before: Jiangsu Cobain Pharmaceutical Co., Ltd. Patentee before: Hangzhou Coben Pharmaceutical Co., Ltd. Co-patentee before: Hangzhou Coben Pharmaceutical Research Co., Ltd. |